Inovio Pharmaceuticals (Formerly Known as Inovio Biomedical Corporation)'s Novel DNA Vaccine for Clade C HIV Achieves Immune Responses and Protection in Non-Human Primates

(BUSINESS WIRE)--Inovio Pharmaceuticals, Inc. (NYSE Amex:INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper highlighting positive preclinical results from Inovio’s novel DNA vaccine targeting HIV Clade C viruses in the journal Vaccine. Clade C is the predominant HIV-1 strain infecting people in sub-Saharan Africa, India, and China, and there is a critical need for a vaccine targeted to these areas.